Top

Current Fungal Infection Reports

Published in:

01-09-2021 | Candidiasis | Advances in Diagnosis of Invasive Fungal Infections (O Morrissey, Section Editor)

Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory

Authors: C. Keighley, K. Garnham, S. A. J. Harch, M. Robertson, K. Chaw, J. C. Teng, S. C.-A. Chen

Published in: Current Fungal Infection Reports | Issue 3/2021

Abstract

Purpose of Review

This review summarises the epidemiology of Candida auris infection and describes contemporary and emerging diagnostic methods for detection and identification of C. auris.

Recent Findings

A fifth C. auris clade has been described. Diagnostic accuracy has improved with development of selective/differential media for C. auris. Advances in spectral databases of matrix-associated laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) systems have reduced misidentification. Direct detection of C. auris in clinical specimens using real time PCR is increasingly used, as is whole genome sequencing (WGS) to track nosocomial spread and to study phylogenetic relationships and drug resistance.

Summary

C. auris is an important transmissible, nosocomial pathogen. The microbiological laboratory diagnostic capacity has extended beyond culture-based methods to include PCR and WGS. Microbiological techniques on the horizon include the use of MALDI-TOF MS for early echinocandin antifungal susceptibility testing (AST) and expansion of the versatile and information-rich WGS methods for outbreak investigation.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4. https://doi.org/10.1111/j.1348-0421.2008.00083.x.CrossRefPubMed

Biswas C, Wang Q, van Hal SJ, Eyre DW, Hudson B, Halliday CL, et al. Genetic heterogeneity of Australian Candida auris isolates: insights from a non-outbreak setting using whole-genome sequencing. Open Forum Infect Dis. 2020;7(5):ofaa158. https://doi.org/10.1093/ofid/ofaa158.CrossRefPubMedPubMedCentral

Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31(1). https://doi.org/10.1128/CMR.00029-17.

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–40. https://doi.org/10.1093/cid/ciw691.CrossRefPubMed

• Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25(9):1780–1. https://doi.org/10.3201/eid2509.190686Description of fifth clade of C. auris.CrossRefPubMedPubMedCentral

• Kean R, Brown J, Gulmez D, Ware A, Ramage G. Candida auris: a decade of understanding of an enigmatic pathogenic yeast. J Fungi. 2020;6(1). https://doi.org/10.3390/jof6010030Excellent review including epidemiology.

Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Medical mycology. 2019;57(1):1–12. https://doi.org/10.1093/mmy/myy054.CrossRefPubMed

• Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, et al. Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. Intern Med J. 2019;49(10):1229–43. https://doi.org/10.1111/imj.14612Australian guidelines; concise overview.CrossRefPubMed

Al Maani A, Paul H, Al-Rashdi A, Wahaibi AA, Al-Jardani A, Al Abri AMA, et al. Ongoing challenges with healthcare-associated Candida auris outbreaks in Oman. J Fungi (Basel). 2019;5(4). https://doi.org/10.3390/jof5040101.

10.

Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, Aleixandre-López AI, Martínez-Morel H, Calabuig E, et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018;61(7):498–505. https://doi.org/10.1111/myc.12781.CrossRefPubMed

11.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging. Antimicrob Resist Infect Control. 2016;5:35. https://doi.org/10.1186/s13756-016-0132-5.CrossRefPubMedPubMedCentral

12.

van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H, Lowman W, et al. Epidemiologic shift in Candidemia driven by Candida auris, South Africa, 2016-2017. Emerg Infect Dis. 2019;25(9):1698–707. https://doi.org/10.3201/eid2509.190040.CrossRefPubMedPubMedCentral

13.

Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41(2):285–95. https://doi.org/10.1007/s00134-014-3603-2.CrossRefPubMed

14.

Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, et al. Candida auris in Healthcare Facilities, New York, USA, 2013-2017. Emerg Infect Dis. 2018;24(10):1816–24. https://doi.org/10.3201/eid2410.180649.CrossRefPubMedPubMedCentral

15.

Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290. https://doi.org/10.1371/journal.ppat.1006290.CrossRefPubMedPubMedCentral

16.

Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant. 2017;17(1):296–9. https://doi.org/10.1111/ajt.14121.CrossRefPubMed

17.

Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379(14):1322–31. https://doi.org/10.1056/NEJMoa1714373.CrossRefPubMed

18.

Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61(6). https://doi.org/10.1128/aac.00485-17.

19.

Worth LJ, Harrison SJ, Dickinson M, van Diemen A, Breen J, Harper S, et al. Candida auris in an Australian health care facility: importance of screening high risk patients. Med J Aust. 2020;212(11):510-1 e1. https://doi.org/10.5694/mja2.50612.

20.

• Centers for Disease Control and Prevention. Tracking Candida auris. (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html#world). Accessed 1st August 2020. An informative, user friendly guide to laboratory diagnostic methods, the CDC algorithm is useful to those working in similarly resourced laboratories.

21.

Karmarkar E, O'Donnell K, Prestel C, Forsberg K, Schan D, Chow N, et al. Regional assessment and containment of Candida auris transmission in post-acute care settings - Orange County, California, 2019. Open Forum Infectious Diseases. 2019;6:S993. https://doi.org/10.1093/ofid/ofz415.2484.CrossRefPubMedCentral

22.

Kohlenberg A, Struelens M, Monnet D. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013-2017. D Pla, Eurosurveillance. 2018;23(13). https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136.

23.

Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139–42. https://doi.org/10.1128/JCM.00319-11.CrossRefPubMedPubMedCentral

24.

Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, et al. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 2017;97(4):363–70. https://doi.org/10.1016/j.jhin.2017.09.009.CrossRefPubMed

25.

Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species. Infect Control Hosp Epidemiol. 2017;38(9):1107–9. https://doi.org/10.1017/ice.2017.127.CrossRefPubMed

26.

• Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55(10):2996–3005. https://doi.org/10.1128/JCM.00921-17Describes the persistence of C. auris on surfaces.CrossRefPubMedPubMedCentral

27.

Pacilli M, Kerins JL, Clegg WJ, Walblay KA, Adil H, Kemble SK, et al. Regional emergence of Candida auris in Chicago and lessons learned from intensive follow-up at one ventilator-capable skilled nursing facility. Clin Infect Dis. 2020;71:e718–25. https://doi.org/10.1093/cid/ciaa435.CrossRefPubMed

28.

Tsay S, Welsh RM, Adams EH, Chow NA, Gade L, Berkow EL, et al. Notes from the field: ongoing transmission of Candida auris in health care facilities - United States, June 2016-May 2017. MMWR Morbidity and mortality weekly report. 2017;66(19):514–5. https://doi.org/10.15585/mmwr.mm6619a7.CrossRefPubMedPubMedCentral

29.

Centers for Disease Control and Prevention. Identification of Candida auris. https://www.cdc.gov/fungal/candida-auris/identification.html? CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fcandida-auris%2Frecommendations.html. Accessed 1st August 2020.

30.

Chibabhai V, Fadana V, Bosman N, Nana T. Comparative sensitivity of 1,3 beta-D-glucan for common causes of candidaemia in South Africa. Mycoses. 2019;62(11):1023–8. https://doi.org/10.1111/myc.12982.CrossRefPubMed

31.

• Chew SM, Sweeney N, Kidd SE, Reed C. Candida auris arriving on our shores: an Australian microbiology laboratory's experience. Pathology. 2019;51(4):431–3. https://doi.org/10.1016/j.pathol.2019.01.009A description of the identification of C. auris in Australia.CrossRefPubMed

32.

• Borman AM, Fraser M, Johnson EM. CHROMagarTM Candida Plus: a novel chromogenic agar that permits the rapid identification of Candida auris. Medical mycology. 2020. https://doi.org/10.1093/mmy/myaa049Report of a novel chromogenic agar.

33.

Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53(6):1823–30. https://doi.org/10.1128/jcm.00367-15.CrossRefPubMedPubMedCentral

34.

Szekely A, Borman AM, Johnson EM. Candida auris isolates of the Southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J Clin Microbiol. 2019;57(5). https://doi.org/10.1128/jcm.02055-18.

35.

Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol. 2012;50(11):3641–51. https://doi.org/10.1128/JCM.02248-12.CrossRefPubMedPubMedCentral

36.

Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, et al. New clonal strain of Candida auris, Delhi. India. Emerg Infect Dis. 2013;19(10):1670–3. https://doi.org/10.3201/eid1910.130393.CrossRefPubMed

37.

Fraser M, Brown Z, Houldsworth M, Borman AM, Johnson EM. Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database. Medical mycology. 2016;54(1):80–8. https://doi.org/10.1093/mmy/myv085.CrossRefPubMed

38.

Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect. 2015;21(4):372–8. https://doi.org/10.1016/j.cmi.2014.11.009.CrossRefPubMed

39.

Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55(2):638–40. https://doi.org/10.1128/JCM.02202-16.CrossRefPubMedPubMedCentral

40.

Grenfell RC, da Silva Junior AR, Del Negro GM, Munhoz RB, Gimenes VM, Assis DM, et al. Identification of Candida haemulonii Complex Species: Use of ClinProTools(TM) to Overcome Limitations of the Bruker Biotyper(TM), VITEK MS(TM) IVD, and VITEK MS(TM) RUO Databases. Front Microbiol. 2016;7:940. https://doi.org/10.3389/fmicb.2016.00940.CrossRefPubMedPubMedCentral

41.

RCPAQAP. Mycology Generic Report. Sydney, Australia: the Royal College of Pathologists of Australasia Quality Assurance Program (RCPAQAP)2018 25/10/2018.

42.

Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, et al. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry. Mycoses. 2016;59(8):535–8. https://doi.org/10.1111/myc.12519.CrossRefPubMed

43.

• Vatanshenassan M, Boekhout T, Meis JF, Berman J, Chowdhary A, Ben-Ami R, et al. Candida auris identification and rapid antifungal susceptibility testing against Echinocandins by MALDI-TOF MS. Front Cell Infect Microbiol. 2019;9:20. https://doi.org/10.3389/fcimb.2019.00020An interesting description of future use of MALDI-TOF potential.CrossRefPubMedPubMedCentral

44.

• Almaghrabi RS, Albalawi R, Mutabagani M, Atienza E, Aljumaah S, Gade L, et al. Molecular characterisation and clinical outcomes of Candida auris infection: single-centre experience in Saudi Arabia. Mycoses. 2020;63(5):452–60. https://doi.org/10.1111/myc.13065.CrossRefPubMed

45.

• ElBaradei A. A decade after the emergence of Candida auris: what do we know? Eur J Clin Microbiol Infect Dis. 2020. doi:10.1007/s10096-020-03886-9. Excellent review including epidemiology.

46.

• Kordalewska M, Perlin DS. Molecular diagnostics in the times of surveillance for Candida auris. J Fungi (Basel). 2019;5(3). https://doi.org/10.3390/jof5030077Excellent review focusing on molecular diagnostics and mechanisms of resistance in C. auris.

47.

Osei SJ. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2018;7(4):e00578. https://doi.org/10.1002/mbo3.578.CrossRef

48.

Kordalewska M, Lee A, Park S, Berrio I, Chowdhary A, Zhao Y, et al. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother. 2018;62(6). https://doi.org/10.1128/aac.00238-18.

49.

Lima A, Widen R, Vestal G, Uy D, Silbert S. A TaqMan probe-based real-time PCR assay for the rapid identification of the emerging multidrug-resistant pathogen Candida auris on the BD max system. Journal of Clinical Microbiology. 2019;57(7):e01604–18. https://doi.org/10.1128/JCM.01604-18.CrossRefPubMedPubMedCentral

50.

Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V. A rapid and automated sample-to-result Candida auris real-time PCR assay for high-throughput testing of surveillance samples with the BD max open system. J Clin Microbiol. 2019;57(10). https://doi.org/10.1128/JCM.00630-19.

51.

Sexton DJ, Kordalewska M, Bentz ML, Welsh RM, Perlin DS, Litvintseva AP. Direct detection of emergent fungal pathogen Candida auris in clinical skin swabs by SYBR green-based quantitative PCR assay. Journal of Clinical Microbiology. 2018;56(12):e01337–18. https://doi.org/10.1128/JCM.01337-18.CrossRefPubMedPubMedCentral

52.

Yamamoto M, Alshahni MM, Tamura T, Satoh K, Iguchi S, Kikuchi K, et al. Rapid detection of Candida auris based on loop-mediated isothermal amplification (LAMP). Journal of Clinical Microbiology. 2018;56(9):e00591–18. https://doi.org/10.1128/JCM.00591-18.CrossRefPubMedPubMedCentral

53.

Oh BJ, Shin JH, Kim MN, Sung H, Lee K, Joo MY, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Medical mycology. 2011;49(1):98–102. https://doi.org/10.3109/13693786.2010.493563.CrossRefPubMed

54.

Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. Pharmacodynamic optimization for treatment of invasive Candida auris infection. Antimicrob Agents Chemother. 2017;61(8). https://doi.org/10.1128/aac.00791-17.

55.

Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891–9. https://doi.org/10.1093/jac/dkx480.CrossRefPubMed

56.

Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018;90(3):196–7. https://doi.org/10.1016/j.diagmicrobio.2017.10.021.CrossRefPubMed

57.

Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. https://doi.org/10.1038/s41467-018-07779-6.CrossRefPubMedPubMedCentral

58.

Healey KR, Kordalewska M, Jiménez Ortigosa C, Singh A, Berrío I, Chowdhary A et al. Limited ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility. Antimicrob Agents Chemother. 2018;62(10). doi:10.1128/aac.01427-18.

59.

Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, et al. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect. 2018;7(1):43–12. https://doi.org/10.1038/s41426-018-0045-x.CrossRefPubMedPubMedCentral

60.

Hou X, Lee A, Jiménez-Ortigosa C, Kordalewska M, Perlin DS, Zhao Y. Rapid detection of ERG11-Associated azole resistance and FKS-associated echinocandin resistance in Candida auris. Antimicrobial Agents and Chemotherapy. 2019;63(1):e01811–8. https://doi.org/10.1128/AAC.01811-18.CrossRefPubMed

61.

Kwon YJ, Shin JH, Byun SA, Choi MJ, Won EJ, Lee D, et al. Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2019;57(4). https://doi.org/10.1128/jcm.01624-18.

62.

Delavy M, Dos Santos AR, Heiman CM, Coste AT. Investigating antifungal susceptibility in Candida Species with MALDI-TOF MS-based assays. Front Cell Infect Microbiol. 2019;9:19. https://doi.org/10.3389/fcimb.2019.00019.CrossRefPubMedPubMedCentral

63.

Hata DJ, Humphries R, Lockhart SR. Candida auris: an emerging yeast pathogen posing distinct challenges for laboratory diagnostics, treatment, and infection prevention. Archives of pathology & laboratory medicine. 2020;144(1):107–14. https://doi.org/10.5858/arpa.2018-0508-RA.CrossRef

64.

Pekard-Amenitsch S, Schriebl A, Posawetz W, Willinger B, Kölli B, Buzina W. Isolation of Candida auris from ear of otherwise healthy patient, Austria, 2018. Emerging Infectious Disease journal. 2018;24(8):1596–7. https://doi.org/10.3201/eid2408.180495.CrossRef

65.

Letscher-Bru V, Meyer M-H, Galoisy A-C, Waller J, Candolfi E. Prospective evaluation of the new chromogenic medium Candida ID, in comparison with Candiselect, for isolation of molds and isolation and presumptive identification of yeast species. Journal of Clinical Microbiology. 2002;40(4):1508–10. https://doi.org/10.1128/JCM.40.4.1508-1510.2002.CrossRefPubMedPubMedCentral

66.

Mulet Bayona JV, García CS, Palop NT, Cardona CG. Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar™ Candida for the detection of Candida auris in surveillance samples. Diagnostic Microbiology and Infectious Disease. 2020. https://doi.org/10.1016/j.diagmicrobio.2020.115168.

Title: Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory
Authors: C. Keighley
K. Garnham
S. A. J. Harch
M. Robertson
K. Chaw
J. C. Teng
S. C.-A. Chen
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Candidiasis
Candidiasis
Laser
Published in: Current Fungal Infection Reports / Issue 3/2021
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-021-00420-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2021

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Emergence of Triazole Resistance in Aspergillus spp. in Latin America

Molecular Diagnosis of Yeast Infections

Scedosporium and Lomentospora infections in lung transplant recipients

Cytopathology of Fungal Infections

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage